SOAM
BBIO icon

SBI Okasan Asset Management’s BridgeBio Pharma BBIO Stock Holding History

SBI Okasan Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605K Hold
8,400
– – 0.02% 201
2026
Q1 		$583K Buy
+8,400
New +$609K 0.02% 179

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

SBI Okasan Asset Management's BBIO Position: Q2 2026 in Review

SBI Okasan Asset Management held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 8,400 shares worth $605K. The position accounts for 0.02% of the portfolio, ranked #201.

SBI Okasan Asset Management first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • SBI Okasan Asset Management held 8,400 shares of BridgeBio Pharma worth $605K as of Q2 2026.
  • SBI Okasan Asset Management left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.02% of SBI Okasan Asset Management's portfolio in Q2 2026, its #201 holding.
  • SBI Okasan Asset Management first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.